Quick Answer
MapLight Therapeutics, Inc. reported Operating Income of -$169.08 million for fiscal year 2025.
MapLight Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$169.08M | -103.8% |
| 2024 | -$82.95M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$31.50M | -50.8% | -50.8% |
| September 30, 2024 | -$20.89M | — | — |
- MapLight Therapeutics, Inc. showed a decrease of -103.8% in Operating Income compared to the prior fiscal year.
- Over the 2024–2025 period, MapLight Therapeutics, Inc.’s operating income has declined by 103.8% (from -$82.95 million to -$169.08 million).
- The most recent figure is from MapLight Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: